Business Daily from THE HINDU group of publications
Thursday, Dec 28, 2006
ePaper
Business Daily from THE HINDU group of publications Thursday, Dec 28, 2006 ePaper |
|
|
|
|
|
|
|
Marketing
-
New Products & Services Wockhardt launches Ondansetron injection in US Our Bureau
Mumbai , Dec. 27 Wockhardt Ltd's subsidiary Wockhardt USA Inc launched its Ondansetron injection in the US on Tuesday, the company announced in a statement posted on the Bombay Stock Exchange on Wednesday. Ondansetron is the generic version of GlaxoSmithKline's Zofran injection, used to help control nausea and vomiting following cancer chemotherapy. The patent for Zofran expired on December 24. "This is Wockhardt's eighth product approval from US FDA in 2006 and the third injection product in the US market," said the Wockhardt Chairman, Mr Habil Khorakiwala, in a statement. "We now market 15 products in the US, 10 of them launched during 2006." The Ondansetron injection is manufactured at the company's sterile formulation plant in Waluj, Aurangabad, a facility certified by the USFDA. The company has two other sterile formulation plants approved by USFDA in India and the UK. US sales of the Zofran injection for the 12 months ended September 30, 2006, were $628 million.
More Stories on : New Products & Services | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2006, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|